No black box warning on record for Mitomycin

As of the latest FDA labeling reviewed, Mitomycin (MITOMYCIN) does not carry a black box warning. Standard warnings and precautions still apply — see the full Mitomycin medicine page for the complete safety profile.

Other warnings & precautions

WARNINGS Patients being treated with mitomycin must be observed carefully and frequently during and after therapy. The use of mitomycin results in a high incidence of bone marrow suppression, particularly thrombocytopenia and leukopenia. Therefore, the following studies should be obtained repeatedly during therapy and for at least eight weeks following therapy: platelet count, white blood cell cou

No black box warning on record for Mitomycin

Other warnings & precautions

WARNINGS Patients being treated with mitomycin must be observed carefully and frequently during and after therapy. The use of mitomycin results in a high incidence of bone marrow suppression, particularly thrombocytopenia and leukopenia. Therefore, the following studies should be obtained repeatedly during therapy and for at least eight weeks following therapy: platelet count, white blood cell cou

Mitomycin Black Box Warning

No black box warning on record for Mitomycin

Other warnings & precautions

Mitomycin Black Box Warning

No black box warning on record for Mitomycin

Other warnings & precautions